Publisher's Synopsis
The Human Immunodeficiency Virus (HIV) is one of the most common sexually transmitted diseases (STDs) today and has the highest transmission rates. Infected people have an increased risk of developing certain types of lymphoma. The prognosis of these patients is mainly related to the lymphoma, the patient and the HIV infection. Treatment for HIV with antiretroviral therapy (ART) has led to an increase in the survival of these patients. Due to the good evolution of treatment in HIV-positive patients, it has been possible to treat lymphomas related to the disease using standard chemotherapy. However, in Brazil, the use of Rituximab is not yet permitted by the Unified Health System. This could end up affecting the quality and survival of these patients. The aim of the study was to characterize the population, their treatments and clinical responses to the treatment made available by the SUS.
